Inquis Medical, Inc., a privately held medical technology company dedicated to advancing mechanical thrombectomy for venous ...

The Cellares Cell Shuttle platform was the first to receive the FDA’s Advanced Manufacturing Technology (AMT) designation, which offers partners additional touchpoints and priority review mechanisms ...

Autolus Therapeutics plc , a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first Integrated ...

A 1000 ng/mL D-dimer threshold safely rules out pulmonary embolism in low-likelihood patients, reducing unnecessary chest imaging in emergency care.

Dublin, Dec. 19, 2025 (GLOBE NEWSWIRE) -- The "Pulmonary Embolism Market - A Global and Regional Analysis, 2025-2035" has been added to ResearchAndMarkets.com's offering. The global pulmonary embolism ...

Pulmonary embolism (PE) is the third most common heart and blood vessel disease after heart attack and stroke. Yet it is frequently misdiagnosed as pneumonia, a mistake that continues to claim lives.

Reduced diffusing capacity of the lungs for carbon monoxide (DLco) reflects microvasculopathy in chronic thromboembolic ...

A new international study led by researchers from UNSW Sydney's Center for Healthy Brain Aging (CHeBA) has developed the ...

Doctors are being forced to delay surgery for some patients who are on Ozempic-like drugs, which can pose a heightened risk of life-threatening consequences to patients when they are under anaesthesia ...

Investing.com -- AI-related valuation risk has emerged as the single biggest threat to market stability in 2026, according to Deutsche Bank’s latest global markets survey, which gathered 440 responses ...

Forbes contributors publish independent expert analyses and insights. Korok Ray is a PhD economist/professor who researches/teaches Bitcoin. Bitcoin mining looks like a heavy industrial process—rows ...

Autolus will evaluate Cellares' fully automated, high-throughput manufacturing platform in preparation for expansion into new indications Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage ...